The Prevalence of Drug Resistance Among Treatment-naïve HIV-1-infected Individuals in China During Pre- and Post- 2004

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2016 Oct 27

PMID 27782811

Citations 7

Authors

Hanping Li

Shuai Chang

Yang Han

Daomin Zhuang

Lin Li

Yongjian Liu

Siyang Liu

Zuoyi Bao

Wenfu Zhang

Hongbin Song

Taisheng Li

Jingyun Li

Affiliations

Soon will be listed here.

Abstract

Background: The widespread use of antiretroviral therapies has led to considerable concerns about the prevalence of drug-resistant, as transmission of drug-resistant (TDR) strains poses a challenge for the control of the HIV-1 epidemic.

Methods: We conducted an epidemiological study enrolling treatment-naïve HIV-1-positive subjects at the Peking Union Medical College Hospital since 1991. Drug resistance was determined by submitting the sequences to the Stanford University Network HIV-1 database.

Results: Of 521 participants, 478 samples were amplified and sequenced successfully. HIV Transmitted drug resistance prevalence in China was determined to be 6.7 %. We did not find significant differences in the TDR rate by demographic characteristics. No significant time trend in the prevalence of overall TDR was observed (p > 0.05).

Conclusions: We identified an intermediate prevalence of transmitted drug resistance (TDR), exhibiting a stable time trend. These findings enhance our understanding of HIV-1 drug resistance prevalence and time trend, and provide some guidelines for the comprehensive public health strategy of TDR prevention.

Citing Articles

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes.

Cilento M, Wen X, Reeve A, Ukah O, A Snyder A, Carrillo C Viruses. 2023; 15(10).

PMID: 37896768 PMC: 10612037. DOI: 10.3390/v15101990.

Multi-Clinical Factors Combined with an Artificial Intelligence Algorithm Diagnosis Model for HIV-Infected People with Bloodstream Infection.

Wu L, Xia D, Xu K Infect Drug Resist. 2023; 16:6085-6097.

PMID: 37719647 PMC: 10503519. DOI: 10.2147/IDR.S423709.

Characterization of HIV-1 molecular epidemiology and transmitted drug-resistance in newly diagnosed HIV-infected patients in Sichuan, China.

Zhou C, Liang S, Li Y, Zhang Y, Li L, Ye L BMC Infect Dis. 2022; 22(1):602.

PMID: 35799101 PMC: 9263063. DOI: 10.1186/s12879-022-07576-z.

Evaluation of the Outcome of Antiviral Therapy among Individuals Infected HIV-1 in Suqian District of Jiangsu Province, China.

Zhang Z, Su J, Shen X, Pei B, Zhu F, Ji H Iran J Public Health. 2021; 50(8):1586-1594.

PMID: 34917529 PMC: 8643539. DOI: 10.18502/ijph.v50i8.6804.

Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges.

Cao W, Hsieh E, Li T Curr HIV/AIDS Rep. 2020; 17(1):26-34.

PMID: 31939111 PMC: 6989417. DOI: 10.1007/s11904-019-00478-x.

References

Chan P, Kantor R . Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther. 2010; 3(5):447-465. PMC: 2800377. DOI: 10.2217/hiv.09.30. View

Castor D, Low A, Evering T, Karmon S, Davis B, Figueroa A . Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr. 2012; 61(1):1-8. PMC: 3427460. DOI: 10.1097/QAI.0b013e31825a289b. View

Frange P, Assoumou L, Descamps D, Cheret A, Goujard C, Tran L . HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies. J Antimicrob Chemother. 2015; 70(7):2084-9. DOI: 10.1093/jac/dkv049. View

Vercauteren J, Wensing A, van de Vijver D, Albert J, Balotta C, Hamouda O . Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009; 200(10):1503-8. DOI: 10.1086/644505. View

Zhang L, Chen Z, Cao Y, Yu J, Li G, Yu W . Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol. 2004; 78(24):13591-9. PMC: 533913. DOI: 10.1128/JVI.78.24.13591-13599.2004. View

Roberts J, Bebenek K, Kunkel T . The accuracy of reverse transcriptase from HIV-1. Science. 1988; 242(4882):1171-3. DOI: 10.1126/science.2460925. View

Han X, An M, Zhang W, Cai W, Chen X, Takebe Y . Genome Sequences of a Novel HIV-1 Circulating Recombinant Form, CRF55_01B, Identified in China. Genome Announc. 2013; 1(1). PMC: 3569284. DOI: 10.1128/genomeA.00050-12. View

Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, Minami R . Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res. 2010; 88(1):72-9. DOI: 10.1016/j.antiviral.2010.07.008. View

Frentz D, Boucher C, van de Vijver D . Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 2012; 14(1):17-27. View

10.

Grgic I, Zidovec Lepej S, Lunar M, Poljak M, Vince A, Vrakela I . The prevalence of transmitted drug resistance in newly diagnosed HIV-infected individuals in Croatia: the role of transmission clusters of men who have sex with men carrying the T215S surveillance drug resistance mutation. AIDS Res Hum Retroviruses. 2012; 29(2):329-36. PMC: 3552172. DOI: 10.1089/aid.2012.0191. View

11.

He N, Detels R . The HIV epidemic in China: history, response, and challenge. Cell Res. 2005; 15(11-12):825-32. DOI: 10.1038/sj.cr.7290354. View

12.

Haase A . Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol. 1999; 17:625-56. DOI: 10.1146/annurev.immunol.17.1.625. View

13.

Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, Burgisser P . Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS. 2007; 21(16):2223-9. DOI: 10.1097/QAD.0b013e3282f0b685. View

14.

Cane P, Chrystie I, Dunn D, Evans B, Geretti A, Green H . Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005; 331(7529):1368. PMC: 1309643. DOI: 10.1136/bmj.38665.534595.55. View

15.

Chen M, Ma Y, Duan S, Xing H, Yao S, Su Y . Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China. BMC Infect Dis. 2012; 12:382. PMC: 3552723. DOI: 10.1186/1471-2334-12-382. View

16.

Wensing A, van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E . Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005; 192(6):958-66. DOI: 10.1086/432916. View

17.

Sendi P, Gunthard H, Simcock M, Ledergerber B, Schupbach J, Battegay M . Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS One. 2007; 2(1):e173. PMC: 1769464. DOI: 10.1371/journal.pone.0000173. View

18.

Su B, Liu L, Wang F, Gui X, Zhao M, Tien P . HIV-1 subtype B' dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. AIDS. 2003; 17(17):2515-20. DOI: 10.1097/00002030-200311210-00015. View

19.

Chaix M, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C . Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS. 2009; 23(6):717-24. DOI: 10.1097/QAD.0b013e328326ca77. View

20.

Little S, Holte S, Routy J, Daar E, Markowitz M, Collier A . Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002; 347(6):385-94. DOI: 10.1056/NEJMoa013552. View